Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
Sherene Loi(Peter MacCallum Cancer Centre), Anita Giobbie‐Hurder(Dana-Farber Cancer Institute), Andrea Gombos(Institut Jules Bordet), Thomas Bachelot(Centre Léon Bérard), Rina Hui(Westmead Hospital), Giuseppe Curigliano(European Institute of Oncology), Mario Campone(Institut de Cancérologie de l'Ouest), Laura Biganzoli, Hervé Bonnefoi(Institut Bergonié), Guy Jérusalem(University of Liège), Rupert Bartsch(Medical University of Vienna), Manuela Rabaglio(University Hospital of Bern), Roswitha Kammler(International Breast Cancer Study Group), Rudolf Maibach(International Breast Cancer Study Group), Mark J. Smyth(QIMR Berghofer Medical Research Institute), Angelo Di Leo, Marco Colleoni(European Institute of Oncology), Giuseppe Viale(International Breast Cancer Study Group), Meredith M. Regan(Harvard University), Fabrice André(Institut Gustave Roussy), Debora Fumagalli, Richard D. Gelber, Theodora Goulioti, Anita Hiltbrunner(Dana-Farber Cancer Institute), Rita L. Hui(Westmead Hospital), Heidi Roschitzki, Barbara Ruepp, Frances M. Boyle, Rolf A. Stahel, Stefan Aebi, Alan S. Coates, Aron Goldhirsch, Per Karlsson(Medical University of Vienna), Ingrid Kössler, Stamatina Fournarakou, Adriana Gasca, Rita Pfister, Sabrina Ribeli-Hofmann, Magdelena Weber, Daniela Celotto, Carmen Comune, M. Frapolli, Magdalena Sánchez-Hohl, Hui Huang(Westmead Hospital), Caitlin Mahoney, Karen N. Price, Karolyn Scott, Holly Shaw, Susan M. Fischer, Mónica Greco, Colleen King, Stefania Andrighetto, Martine Piccart, Heather E. Findlay, Michelle Jenkins, Vassiliki Karantza, Jaime Mejia, Patrick Schneier
Cited by 476
Abstract
Related Papers
No related papers found
Powered by citation graph analysis